- Location:
- Charles Russell, 5 Fleet Place, London EC4M 7RD
- Date:
- 12 October 2011
Sponsored and hosted by
Due to the success of our Life Science Leadership Series - Oncology event earlier in the year and the continued engagement of that group, we have elected to run a follow on One Nucleus Oncology Networking Seminar. This event will continue the showcasing of leading companies, and the thought leadership around trends in financing, regulatory and market access strategies.
The event is timed to coincide with the week of BioPartnering Europe in London in order to engage with visiting overseas companies and investors
It will be hosted in a convenient central London location at the offices of Charles Russell with a maximum 100 delegates to ensure focus and quality of networking opportunity on the day.
Programme:
08.30 - Registration
09.00 - Welcome -
Harriet Fear, One Nucleus
09.10 -
Plenary Presentation: Will Open innovation Revolutionise the Science and Finance Aspects of Drug Discovery?
Prof Chas Bountra, Head of the Structural Genomics Consortium, University of Oxford
09.30 -
Analysis of Human Tissues in Drug and Biomarker Development: from Tissue Acquisition to Image Analysis
Madhuri Warren, CEO, Pathology Diagnostics
09.50 -
Plenary Presentation: Protecting Yourself in the Dealmaking Food Chain
Jenny Pierce, Partner - Charles Russell
10.10 -
Planary Speaker TBC
10.30 - Tea/Coffee Break and networking
11.15 - Latest Advances in Systems Biology and Biomarkers
11.15 - Introduction from the Chair -
Davidson Ateh, CEO BioMoti
11.20 -
Targeting DNA Repair Mechanisms in Cancer Therapy
Niall Martin, COO, Mission Therapeutics
11.35 -
Network Pharmacology: Systematic Drug Discovery
Malcolm Young, CEO, e-Therapeutics
11.50 -
Virtual Tumour Platform to Predict Optimal Dosing Regimens
Mark Chadwick, CEO, Physiomics plc
12.05 - Innovative Discovery Chemistry Approaches to Ubiquitin Proteasome-Based Targets
Bill Blair, Founder UB Pharma
12.20 -
Cell Accumulation of Drug Through ESM Technology
Scott Cuthill, Associate Director, Business Development , Chroma Therapeutics
12.35 - Lunch, exhibitor visits and networking
13.45 -
Immune-Based Therapeutics
13.45 - Introduction from the Chair -
Austin Smith, Theradex
13.50 -
Combining Nanotechnology and Antibodies in Cancer Diagnosis
Prof. Ivan Roitt, Founder - NALIA Systems Ltd
14.05 -
Next Generation Antibody Technology
Tom Shepherd, CBO Kymab
14.20 -
Latest Strategies in Phenotypic Selection in Cancer
Ralph Minter, MedImmune
14.35 -
Integrating Leading Edge Platforms in Antibody-Based Approaches - Please contact
sinead@onenucleus to obtain the slides.
Harry Lamble, Director Business Development , Oxford BioTherapeutics
14.50 -
Generating MAbs to Hitherto Intractable Targets
Facundo Batista, Founder & CSO, BLiNK Therapeutics
15.05 -
Approaches to Immune System Restoration
Didier Coquoz, Chief Development and Business Officer, Cytune Pharma
15.20 - Tea/Coffee Break, exhibitor visits andnetworking
15.50 –
Roadmap to Investment
15.50 -Introduction from the Chair -
Tony Jones, Director of Business Development, One Nucleus
15.55 -
Financing a New Generation of Life Sciences Companies - Please contact
sinead@onenucleus to obtain the slides.
Louis Nisbet, Venture Partner, Kurma Life Sciences Partners
16.15 - Financing Development in India
Tobby Simon, CEO Synergia Bio Sciences
16.35 - Evolving Trends in Corporate Venturing and VC Collaborations
Fraser Campbell, Independent Life Science Finance Consultant
16.55 - Drinks reception
18.30 - Close
Prices:
Gold Members £150 + VAT
Silver Members £250 + VAT
Non-Members £350
+ VAT
About Charles Russell
Charles Russell is a leading law firm based in London with UK regional and international offices in Bahrain and Geneva. The company provide a wide range of legal services to companies, institutions and individuals with a particular focus on certain sectors: Charities & Not-for-Profit, Energy & Natural Resources, Family, Healthcare, Private Wealth, Property, Retail, Design & Leisure, Sports & Media and Technology & Communications.
Key facts
106 Partners, 288 other lawyers and a total staff of 610.
Charles Russell's proposition is to provide highly commercial, business critical, wide-view advice in their areas of specialism. The company provide this in the UK and internationally, we are experienced in carrying out cross-border assignments and are members of two major non-exclusive law firm networks, ALFA International and the Association of European Lawyers.
Services are integrated across all offices and legal disciplines. At Charles Russell "Understanding Relationships" is at the centre of everything. Through understanding the needs of clients, they deliver tailored legal solutions and establish and maintain mutually successful working relationships. This is also fundamental to how the company train and develop their teams and how they work with each other. Our commitment to training and development and unity of purpose underlies our reputation as a respected practice to work with and work for.
Our relationship with the wider community is also very important. Charles Russell recognise their responsibility in every aspect of the company's operations; from the way they operate the business to the ways in which they contribute to the community and manage their impact on the environment.